TY - T1的过度使用短效β2 <子> < /订阅>受体激动剂在哮喘恶化的风险和死亡率增加有关:一个全国性的队列研究的全球萨拜娜项目JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01872 -2019欧元SP - 1901872 AU Nwaru明亮。非盟-埃克斯特龙,马格努斯盟——Hasvold Pal盟的功能——但弗雷德里克•AU - Telg Gunilla AU -詹森,Christer Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/early/2019/12/12/13993003.01872 - 2019. -抽象N2 -背景过度使用短效β2受体激动剂(沙巴)可能表明贫穷哮喘控制和不良健康结果。当代以人群为基础的数据使用,危险因素和萨巴的影响(在)用于哮喘急性加重和死亡率稀缺,促使全球萨比娜的起始(萨巴使用哮喘)计划。方法通过将数据从瑞典国家注册、哮喘患者12-45岁≥2集合阻塞性肺疾病的药物包括2006 - 2014年期间。萨巴过度使用定义为集合在基线期一年2塞巴罐后包容。萨巴使用分成3 - 5、6 - 10和11 +罐/基准年。Cox回归是用来检查萨巴之间的联系使用和恶化(住院治疗上和/或商务索赔)和死亡率。结果分析包括365 324名哮喘患者(平均年龄27.6岁;55%的女性),平均随访85.4个月。约30%的过度使用萨巴,21%收集3 - 5罐,6 - 10 7%和11 + 2%罐·年−1。越来越多的萨巴收集罐与恶化的风险增加:3 - 5 (HR 1.26;95%可信区间1.24 - -1.28);6 - 10 (1.44; 1.41–1.46); and 11+ canisters (1.77; 1.72–1.83) compared to ≤2 canisters·year−1. Higher SABA use was associated with incrementally increased mortality risk (2564 deaths observed): 3–5 (HR 1.26; 95% CI 1.14–1.39); 6–10 (1.67; 1.49–1.87); and 11+ canisters (2.35, 2.02–2.72) compared to ≤2 canisters·year−1.Conclusion One-third of asthma patients in Sweden collected three or more SABA canisters annually. SABA overuse was associated with increased risks of exacerbation and mortality. These findings emphasise that monitoring of SABA usage should be key in improving asthma management.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr Nwaru reports personal fees from AstraZeneca, during the conduct of the study.Conflict of interest: Dr Ekström reports personal fees from AstraZeneca, during the conduct of the study.Conflict of interest: Dr Hasvold reports other from AstraZeneca, during the conduct of the study.Conflict of interest: Dr Telg reports personal fees from Employed by AZ, during the conduct of the study.Conflict of interest: Dr Christer Janson[AQ2] Conflict of interest: Dr Wicklund reports other from Statisticon/AstraZeneca, during the conduct of the study. ER -